Research
Swipe to view
Title : | Antitubercular drugs as dry powder inhalation to improve the treatment of multi-drug resistant tuberculosis |
Area of research : | Engineering Sciences |
Principal Investigator : | Prof. Jitendra Baliram Naik, Kavayitri Bahinabai Chaudhari North Maharashtra University, Jalgaon, Maharashtra |
Timeline Start Year : | 2024 |
Timeline End Year : | 2027 |
Contact info : | jitunaik[at]gmail[dot]com |
Details
Swipe to view
Executive Summary : | Tuberculosis (TB) is a leading public health felonious globally and has a high burden with high mortality, including in India. Our country contributes to one-fourth of the worldwide burden of Multidrug-Resistant Tuberculosis (MDR-TB). The main challenges for controlling tuberculosis in India stem from the underdeveloped primary healthcare infrastructure in rural regions across several states. The unregulated private healthcare sector also exacerbates the problem by promoting widespread and irrational use of first- and second-line antituberculosis drugs (ATDs). To intensify our battle against this deadly tuberculosis, we must develop a new drug regimen or combination drug therapy in dry powder inhalable sustained released ATDs loaded micro-/nanoparticle to deal with tuberculosis. For treating pulmonary TB, dry powder inhaler innovation is a promising approach to delivering drugs by inhalation route to the lungs. Dry powder inhalation (DPIs) is a significant methodology that gives better physicochemical stability and deep lung deposition using patient respiration. Microparticles of ATDs have good potential for direct delivery to the lung when formulated as DPI, which can lower doses & shorter treatment time than conventional drug delivery. The formulation of nano/microparticles for DPIs has the potential to alter the pharmacokinetics and pharmacodynamics of drugs, leading to enhancements in their therapeutic effectiveness. This approach aims to improve the therapeutic index of the drugs. In the realm have scientific literature, the utilization of micro-/nanoparticle as DPI formulations has shown promise in altering biodistribution, in vivo stability, bioavailability, and permeation across biological barriers. Furthermore, these formulations offer the advantage of the controlled and targeted release of the drug. Inhalable micro-/nanoparticle for DPIs have advantageous for improving the solubility, dissolution profiles, and pharmacokinetic profile and reducing premature mucociliary clearance of hydrophobic drugs, masking, facilitation of handling, and protection. |
Total Budget (INR): | 19,76,832 |
Organizations involved
Swipe to view
Implementing Agency : | Kavayitri Bahinabai Chaudhari North Maharashtra University, Jalgaon, Maharashtra |
Funding Agency : | Anusandhan National Rsearch Foundation (ANRF)/Science and Engineering Research Board (SERB) |
Source : | Anusandhan National Research Foundation/Science and Engineering Research Board (SERB), DST 2023-24 |